Physician profile
James Isernia
NPI 1144281148
$16,286.40
in general payments reported to CMS, 2019-2025
66 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $1,458 · 2021: $2,166 · 2022: $317 · 2023: $1,601 · 2024: $6,600 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,738 · Consulting Fee: $2,400 · Travel and Lodging: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.71 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,736.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,201.15 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Novo Nordisk INC | $1,156.64 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,043.40 | 2019-2025 | |
| Ucb, INC. | $791.51 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $637.44 | 2019-2025 | Farxiga, Airsupra, Saphnelo |
| Sanofi-Aventis U.S. LLC | $602.99 | 2019-2025 | |
| Pfizer INC. | $521.87 | 2019-2025 | |
| Janssen Biotech, INC. | $382.53 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $364.89 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.14 | 2019-2025 | Ofev, Jardiance |
| Sunovion Pharmaceuticals INC. | $299.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $295.43 | 2019-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $279.81 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $277.72 | 2019-2021 | |
| Amarin Pharma, INC. | $260.09 | 2019-2021 |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Isernia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.